Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma.
2021
The potential for durvalumab, a programmed cell death ligand-1 (PD-L1)-blocking monoclonal antibody, to treat head and neck squamous cell carcinoma (HNSCC) is being evaluated in multiple clinical t...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
52
References
0
Citations
NaN
KQI